<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02126475</url>
  </required_header>
  <id_info>
    <org_study_id>C12-45</org_study_id>
    <secondary_id>2012-A01056-37</secondary_id>
    <nct_id>NCT02126475</nct_id>
  </id_info>
  <brief_title>Temporal Expectations in Parkinson's Disease</brief_title>
  <acronym>PEDUPARK</acronym>
  <official_title>L'Expectation Temporelle Dans la Maladie de Parkinson : étude Oculomotrice Psychophysique et Par électroencéphalographie</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although major progresses were realized during recent years, temporal cognition is still&#xD;
      poorly understood. However, abnormal temporal cognition is an underestimated aspect of&#xD;
      several neurological disorders, particularly if basal ganglia (BG) are affected. Therefore,&#xD;
      the interest of studying temporal cognition is double: firstly, it is an essential function&#xD;
      necessary to guide all behavior; secondly, it seems to be very sensitive to the integrity of&#xD;
      dopaminergic pathways. It is well known that Parkinson's disease (PD) is partly due to a&#xD;
      degeneration of neurons producing dopamine in the Substantia Nigra pars compacta (SNc).&#xD;
      Therefore, in this project, PD patients and healthy volunteers will be used as a model to&#xD;
      study the role of dopamine in temporal expectation.&#xD;
&#xD;
      An expectation is an internal representation of an event that is likely to occur in the&#xD;
      future. Temporal expectation builds-up as time elapses before the upcoming event. The role of&#xD;
      temporal expectation in the oculomotor domain has often been studied using anticipatory eye&#xD;
      movements as a tool. Indeed, expectation evokes anticipatory eye movements. However, to the&#xD;
      knowledge of the investigators, expectation and anticipation have so far been studied in&#xD;
      experimental tasks where temporal information is essential but not voluntarily controlled.&#xD;
      This is usually referred to as 'automatic' or 'emergent' timing: the timing of the eye&#xD;
      movement adapts to the timing of the target, implicitly and without voluntary control of the&#xD;
      subject. However, anticipatory movements can also be based on an explicit estimation of time,&#xD;
      e.g. during music playing. In summary, timing can be based on cognitive (explicit) or&#xD;
      automatic (implicit) processing. The originality of the behavioral task the investigators&#xD;
      will use in this study is that it will require an explicit comparison of a memorized duration&#xD;
      with elapsing time in order to anticipate target appearance. In this task, expectation of the&#xD;
      upcoming event will build up on explicit temporal information.&#xD;
&#xD;
      Same PD patients will be tested under treatment (&quot;ON&quot;) and without treatment (&quot;OFF&quot;) to&#xD;
      determine the effect of dopamine in time expectation . Only levodopa responsive Parkinson&#xD;
      patients will be included and among them only those receiving levodopa and/or dopa agonists&#xD;
      three times daily at a stable dosis since 30 days.&#xD;
&#xD;
      the investigators hypothesize that eye movements latency will not linearly covary with&#xD;
      objective time in &quot;OFF&quot; PD patients. In treated PD patients, a recovery of the linear&#xD;
      relationship between subjective and objective time is expected. This would clearly&#xD;
      demonstrate the role of dopamine in temporal expectation in humans.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>oculomotor reaction time: saccade latency</measure>
    <time_frame>at least 21 days after inclusion</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Parkinsons Disease</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Park patients</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy volunteers and Parkinson patients, non fluctuent&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy volunteers :&#xD;
&#xD;
               -  Men or women, age: 18 to 65 years old&#xD;
&#xD;
               -  Subject affiliated to a national insurance scheme&#xD;
&#xD;
               -  Informed consent of the study signed&#xD;
&#xD;
               -  Normal neurological exam&#xD;
&#xD;
          2. Patients:&#xD;
&#xD;
               -  Men or women, age: 18 to 65 years old&#xD;
&#xD;
               -  Subject affiliated to a national insurance scheme&#xD;
&#xD;
               -  Informed consent of the study signed&#xD;
&#xD;
               -  Idiopathic Parkinson disease, UKPDSBB criteria (Hughes, Ben-Shlomo, Daniel, &amp;&#xD;
                  Lees, 1992; Hughes, Daniel, Kilford, &amp; Lees, 1992; Hughes, Daniel, &amp; Lees, 2001)&#xD;
&#xD;
               -  Non fluctuant patients&#xD;
&#xD;
               -  Patients treated by L-Dopa +/- other anti-Parkinsonian's, stable dose for 30 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cognitive or behavioural disorder&#xD;
&#xD;
          -  Severe psychiatric symptomatology and psychotropic drug use&#xD;
&#xD;
          -  Subject non-affiliated to a national insurance scheme&#xD;
&#xD;
          -  No signature of the Informed consent of the study&#xD;
&#xD;
          -  Subject freedom-deprived by court or administrative order&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertrand DEGOS, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Département des Maladies du Système Nerveux, Groupe Hospitalier Pitié-Salpêtrière 47-83 boulevard de l'Hôpital 75651 PARIS Cedex 13</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcus MISSAL, Pr-PhD</last_name>
    <role>Study Director</role>
    <affiliation>nstitute of Neurosciences IoNs . Groupe COSY. 53 av. Mounier Boîte B1.53.4 COSY 1200 Bruxelles Belgique</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre POUGET, PhD</last_name>
    <role>Study Director</role>
    <affiliation>ICM, CNRS, INSERM, Université Pierre et Marie Curie Hôpital de la Salpêtrière 47 boulevard de l'Hôpital 75651 Paris CEDEX 13 France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>bertrand DEGOS, PD-PhD</last_name>
    <phone>33-1-42-161762</phone>
    <email>bertrand.degos@psl.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>ICM-IHU</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>ilhame AMEQRANE, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICM</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>bertrand degos, MD-PhD</last_name>
      <email>bertrand.degos@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>ilhame ameqrane, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>April 28, 2014</study_first_submitted>
  <study_first_submitted_qc>April 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2014</study_first_posted>
  <last_update_submitted>February 3, 2015</last_update_submitted>
  <last_update_submitted_qc>February 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>parkinson patients &quot;ON&quot;</keyword>
  <keyword>parkinson patients &quot;OFF&quot;</keyword>
  <keyword>time estimation</keyword>
  <keyword>anticipation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

